MX375341B - Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa. - Google Patents
Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa.Info
- Publication number
- MX375341B MX375341B MX2018001054A MX2018001054A MX375341B MX 375341 B MX375341 B MX 375341B MX 2018001054 A MX2018001054 A MX 2018001054A MX 2018001054 A MX2018001054 A MX 2018001054A MX 375341 B MX375341 B MX 375341B
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- tnf
- alpha
- necrosis factor
- tumor necrosis
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 2
- 102000003390 tumor necrosis factor Human genes 0.000 title 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200424P | 2015-08-03 | 2015-08-03 | |
| PCT/US2016/045110 WO2017023905A1 (en) | 2015-08-03 | 2016-08-02 | Heterocyclic compounds useful as modulators of tnf alpha |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001054A MX2018001054A (es) | 2018-07-06 |
| MX375341B true MX375341B (es) | 2025-03-06 |
Family
ID=56618285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001054A MX375341B (es) | 2015-08-03 | 2016-08-02 | Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10865191B2 (https=) |
| EP (1) | EP3331871A1 (https=) |
| JP (1) | JP6955482B2 (https=) |
| KR (1) | KR102697810B1 (https=) |
| CN (1) | CN108137547B (https=) |
| AR (1) | AR105575A1 (https=) |
| AU (1) | AU2016302144B2 (https=) |
| BR (1) | BR112018001960A2 (https=) |
| CA (1) | CA2994717A1 (https=) |
| CL (1) | CL2018000293A1 (https=) |
| CO (1) | CO2018002061A2 (https=) |
| EA (1) | EA033686B1 (https=) |
| HK (1) | HK1252623A1 (https=) |
| IL (1) | IL257154A (https=) |
| MA (1) | MA43512A (https=) |
| MX (1) | MX375341B (https=) |
| PE (1) | PE20181366A1 (https=) |
| SG (1) | SG10201911831RA (https=) |
| TW (1) | TW201718536A (https=) |
| UY (1) | UY36838A (https=) |
| WO (1) | WO2017023905A1 (https=) |
| ZA (1) | ZA201800716B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| EP3288939A1 (en) | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
| JP2021512898A (ja) * | 2018-02-09 | 2021-05-20 | アメリカ合衆国 | 複素環ｐ２ｙ１４受容体拮抗薬 |
| CN108658977A (zh) * | 2018-04-12 | 2018-10-16 | 苏州康润医药有限公司 | 一种7-溴-1,5-萘啶-3-甲酸的合成方法 |
| CN115803317B (zh) | 2020-05-19 | 2025-07-15 | 拜耳作物科学股份公司 | 作为杀真菌化合物的氮杂双环(硫代)酰胺 |
| WO2021249995A1 (en) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
| US11926632B2 (en) | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| JP2023532888A (ja) | 2020-06-27 | 2023-08-01 | クレセンタ バイオサイエンシズ | 細胞代謝を調節する化合物の組成及び使用方法 |
| JP2023550830A (ja) * | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体 |
| WO2022140456A1 (en) * | 2020-12-22 | 2022-06-30 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
| CN117999263A (zh) * | 2021-09-29 | 2024-05-07 | 上海海和药物研究开发股份有限公司 | 一类具有吡啶并六元环结构的sos1抑制剂 |
| US20240425501A1 (en) * | 2021-10-21 | 2024-12-26 | Sanjita Sasmal | Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors |
| US12138243B2 (en) | 2021-12-31 | 2024-11-12 | Crescenta Biosciences | Antiviral use of FABP4 modulating compounds |
| CN114605409B (zh) * | 2022-04-01 | 2024-04-02 | 苏州睿尔思科技有限公司 | 一种4-羟基-1,5-萘啶类配体的生产制备方法 |
| CN114751858B (zh) * | 2022-04-20 | 2023-09-12 | 沈阳药科大学 | 含有喹啉基的氨甲环酸衍生物及其制备与应用 |
| CN117024404A (zh) * | 2022-05-10 | 2023-11-10 | 四川汇宇制药股份有限公司 | 苯并吡啶衍生物及其用途 |
| US20250084063A1 (en) * | 2023-08-18 | 2025-03-13 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| TW202542130A (zh) * | 2024-01-05 | 2025-11-01 | 美商露點治療股份有限公司 | 胺基喹啉化合物及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US856095A (en) * | 1906-09-01 | 1907-06-04 | Railway Safety Signal Company | Electric semaphore. |
| PH25124A (en) | 1987-03-17 | 1991-02-19 | Hoechst Roussel Pharma | Substituted 9-amino-tetrahydro acridines and related compounds |
| DE3917232A1 (de) * | 1989-05-26 | 1990-11-29 | Basf Ag | 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel |
| KR100745307B1 (ko) | 2001-05-31 | 2007-08-01 | 사노피-아벤티스 | 아미노퀴놀린 유도체 및 아데노신 ａ３ 리간드로서의 이의 용도 |
| AU2002341715A1 (en) * | 2001-09-17 | 2003-04-01 | Bristol-Myers Squibb Company | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| AU2002357312A1 (en) * | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| HUP0105406A3 (en) | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| EP1663982B1 (en) | 2003-07-31 | 2007-11-21 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| JP5599783B2 (ja) * | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| ES2565627T3 (es) * | 2010-07-30 | 2016-04-06 | Oncotherapy Science, Inc. | Derivados de quinolina e inhibidores de MELK que contienen los mismos |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| JP6464139B2 (ja) | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| AR105556A1 (es) | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| EA201892153A1 (ru) | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
-
2016
- 2016-08-02 PE PE2018000172A patent/PE20181366A1/es unknown
- 2016-08-02 MX MX2018001054A patent/MX375341B/es active IP Right Grant
- 2016-08-02 BR BR112018001960A patent/BR112018001960A2/pt not_active IP Right Cessation
- 2016-08-02 EA EA201890165A patent/EA033686B1/ru not_active IP Right Cessation
- 2016-08-02 HK HK18111924.8A patent/HK1252623A1/zh unknown
- 2016-08-02 CA CA2994717A patent/CA2994717A1/en not_active Abandoned
- 2016-08-02 AR ARP160102357A patent/AR105575A1/es unknown
- 2016-08-02 TW TW105124501A patent/TW201718536A/zh unknown
- 2016-08-02 WO PCT/US2016/045110 patent/WO2017023905A1/en not_active Ceased
- 2016-08-02 EP EP16750343.2A patent/EP3331871A1/en not_active Withdrawn
- 2016-08-02 SG SG10201911831RA patent/SG10201911831RA/en unknown
- 2016-08-02 CN CN201680057509.7A patent/CN108137547B/zh active Active
- 2016-08-02 UY UY0001036838A patent/UY36838A/es unknown
- 2016-08-02 AU AU2016302144A patent/AU2016302144B2/en not_active Ceased
- 2016-08-02 MA MA043512A patent/MA43512A/fr unknown
- 2016-08-02 JP JP2018506144A patent/JP6955482B2/ja active Active
- 2016-08-02 KR KR1020187005707A patent/KR102697810B1/ko active Active
- 2016-08-02 US US15/887,214 patent/US10865191B2/en active Active
-
2018
- 2018-01-25 IL IL257154A patent/IL257154A/en unknown
- 2018-02-01 CL CL2018000293A patent/CL2018000293A1/es unknown
- 2018-02-02 ZA ZA2018/00716A patent/ZA201800716B/en unknown
- 2018-02-26 CO CONC2018/0002061A patent/CO2018002061A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20181366A1 (es) | 2018-08-27 |
| JP6955482B2 (ja) | 2021-10-27 |
| AU2016302144B2 (en) | 2020-10-08 |
| MA43512A (fr) | 2018-11-07 |
| EA033686B1 (ru) | 2019-11-15 |
| TW201718536A (zh) | 2017-06-01 |
| CL2018000293A1 (es) | 2018-07-13 |
| EA201890165A1 (ru) | 2018-07-31 |
| AU2016302144A1 (en) | 2018-03-22 |
| HK1252623A1 (zh) | 2019-05-31 |
| EP3331871A1 (en) | 2018-06-13 |
| MX2018001054A (es) | 2018-07-06 |
| JP2018525379A (ja) | 2018-09-06 |
| CO2018002061A2 (es) | 2018-06-20 |
| CN108137547B (zh) | 2021-11-12 |
| US20180222883A1 (en) | 2018-08-09 |
| UY36838A (es) | 2017-01-31 |
| SG10201911831RA (en) | 2020-02-27 |
| CN108137547A (zh) | 2018-06-08 |
| CA2994717A1 (en) | 2017-02-09 |
| WO2017023905A1 (en) | 2017-02-09 |
| US10865191B2 (en) | 2020-12-15 |
| IL257154A (en) | 2018-03-29 |
| AR105575A1 (es) | 2017-10-18 |
| KR20180031772A (ko) | 2018-03-28 |
| KR102697810B1 (ko) | 2024-08-21 |
| ZA201800716B (en) | 2019-07-31 |
| BR112018001960A2 (pt) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375341B (es) | Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa. | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| CY1122314T1 (el) | Κυκλοπροπυλαμινες ως αναστολεις lsd1 | |
| CL2019002461A1 (es) | Arn terapéutico. | |
| MX373154B (es) | Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1). | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| MX2021003389A (es) | Metodos para tratar el cancer. | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| MX377273B (es) | Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1). | |
| EA201790317A1 (ru) | Ингибиторы smyd | |
| MX392537B (es) | Tratamiento del prurito colestasico. | |
| PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
| MX2019013194A (es) | Procedimientos para preparar compuestos de tipo oxatiazina. | |
| UY36747A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| PE20170440A1 (es) | Derivados de isoindolina | |
| BR112018069927A2 (pt) | terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação | |
| UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| CR20140400A (es) | Terapia combinada para el tratamiento del cancer de ovario | |
| CO2017001389A2 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| IL289338A (en) | Therapeutic interactions of leucomethylthioninium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |